Novavax (NASDAQ: NVAX) reported Q4 EPS of ($11.28), $10.73 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $222 million versus the consensus estimate of $442.77 million.

GUIDANCE:

Novavax sees FY2022 revenue of $4-5 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.